Physician profile
Rasheed A Singleton
NPI 1316924558
$13,854.01
in general payments reported to CMS, 2019-2025
34 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $853 · 2021: $599 · 2022: $96.91 · 2023: $774 · 2024: $1,024 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $9,626.35 | 2019 | |
| Boston Scientific Corporation | $1,081.41 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Na |
| Nevro Corp. | $663.43 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $363.02 | 2019-2024 | Belbuca, Xtampza, Nucynta |
| Allergan, INC. | $310.75 | 2019-2021 | |
| Medtronic, INC. | $245.80 | 2023 | Synchromedii, Intellis Adaptivestim |
| Pfizer INC. | $204.03 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.70 | 2019-2023 | Relistor |
| Globus Medical, INC. | $176.53 | 2025 | Senza |
| Ibsa Pharma INC. | $139.60 | 2022-2024 | Tirosint, Licart, Tirosint |
| Abbott Laboratories | $115.69 | 2020-2024 | Proclaim |
| Amgen INC. | $94.99 | 2020 | |
| Lundbeck LLC | $92.76 | 2023 | Vyepti |
| Tersera Therapeutics LLC | $63.30 | 2023-2024 | Prialt |
| Arbor Pharmaceuticals, INC. | $55.40 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $41.94 | 2024 | Hyalgan, Hymovis, Triluron |
| Novartis Pharmaceuticals Corporation | $36.28 | 2019 | |
| Eisai INC. | $35.86 | 2020-2021 | |
| Stimwave Technologies Incorporated | $30.42 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $29.99 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $27.77 | 2019 | |
| Avanos Medical | $26.98 | 2024 | Coolief* Cooled Radiofrequency |
| Averitas Pharma INC. | $23.80 | 2023 | Qutenza |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Abbvie INC. | $20.85 | 2025 | |
| Spr Therapeutics, INC | $18.33 | 2024 | Sprint Pns System |
| Depuy Synthes Sales INC. | $17.73 | 2020 | |
| Daiichi Sankyo INC. | $17.01 | 2019 | |
| Bioventus LLC | $15.86 | 2020 | |
| Shionogi INC | $15.22 | 2019 | |
| Curonix LLC | $14.73 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Assertio Therapeutics, INC. | $12.98 | 2019 | |
| Zyla Life Sciences, INC. | $12.42 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheed Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.